MORPHABOND ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MORPHABOND ER (MORPHABOND ER).
Morphine is a full opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins. Activation of mu receptors leads to G-protein-coupled inhibition of adenylyl cyclase, decreased cAMP production, closure of voltage-gated calcium channels, and opening of potassium channels. This results in reduced neuronal excitability, inhibition of neurotransmitter release (e.g., substance P, glutamate), and modulation of pain signaling pathways, producing analgesia, euphoria, and sedation.
| Metabolism | Primarily metabolized via glucuronidation: morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active) by UGT2B7. Minor metabolism: N-demethylation to normorphine by CYP3A4, and conjugation to morphine-3,6-diglucuronide. Also undergoes sulfation. |
| Excretion | Approximately 90% excreted renally as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), with ~10% excreted unchanged. Fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 11–13 hours in adults, allowing once-daily dosing for MORPHABOND ER. In hepatic impairment, half-life may be prolonged. |
| Protein binding | Approximately 30–35% bound to albumin and, to a lesser extent, α1-acid glycoprotein. |
| Volume of Distribution | 3–4 L/kg; wide distribution indicates extensive tissue uptake, particularly in skeletal muscle, kidneys, liver, and lungs. |
| Bioavailability | Oral extended-release: ~20–40% due to first-pass metabolism. |
| Onset of Action | Oral extended-release: 1–2 hours for analgesic effect. |
| Duration of Action | 12–24 hours with once-daily dosing; analgesic duration is dose-dependent and may require titration. |
15-30 mg orally every 12 hours, titrated to effect; maximum 60 mg per dose or 120 mg daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 25%. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: avoid use or use with extreme caution and reduce dose by 75%. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use. |
| Pediatric use | Not approved for patients under 18 years of age. |
| Geriatric use | Initiate at 50% of adult dose (7.5-15 mg every 12 hours) and titrate cautiously due to increased risk of respiratory depression and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MORPHABOND ER (MORPHABOND ER).
| Breastfeeding | Morphine is excreted into breast milk; the milk-to-plasma (M/P) ratio is approximately 2.5:1. Caution is advised; monitor infant for respiratory depression, sedation, and withdrawal symptoms. |
| Teratogenic Risk | First trimester: Limited data, but opioid use generally not associated with major malformations. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Late third trimester: Use may lead to respiratory depression in neonate. |
| Fetal Monitoring |
■ FDA Black Box Warning
1. Addiction, Abuse, and Misuse: Morphine sulfate extended-release exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. 2. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following dose increases. 3. Accidental Ingestion: Accidental ingestion of even one dose of morphine sulfate extended-release, especially by children, can result in a fatal overdose. 4. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. 5. Interaction with Alcohol: Instruct patients not to consume alcohol or any prescription or over-the-counter medications containing alcohol while on therapy due to increased risk of fatal overdose. 6. Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death.
| Serious Effects |
["Hypersensitivity to morphine or any component of the formulation.","Significant respiratory depression (e.g., acute or severe bronchial asthma, hypercarbia).","Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment.","Known or suspected gastrointestinal obstruction, including paralytic ileus.","Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.","Pregnancy (risk of neonatal opioid withdrawal syndrome); not for use during labor and delivery (prolongs labor)."]
Loading safety data…
| Monitor maternal respiratory status, sedation, and bowel function. Fetal monitoring: Consider nonstress test and biophysical profile in chronic use. For NAS, monitor neonate for 48-72 hours after delivery using standardized scoring tools. |
| Fertility Effects | Chronic opioid use may lead to menstrual cycle irregularities, anovulation, and decreased libido due to hypothalamic-pituitary-gonadal axis suppression. Reversible upon discontinuation. |
| Precautions |
| ["Risk of life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients, and those with chronic pulmonary disease.","Risk of opioid-induced hyperalgesia (OIH) and allodynia with prolonged use.","Risk of severe hypotension in patients with compromised ability to maintain blood pressure (e.g., hypovolemia) or those receiving CNS depressants.","Risk of seizures in patients with seizure disorders or concomitant use with other drugs that lower seizure threshold.","Risk of serotonin syndrome with concomitant serotonergic drugs (e.g., SSRIs, MAOIs).","Adrenal insufficiency may occur with prolonged use; monitor for symptoms.","Androgen deficiency may occur with chronic use.","Use with caution in patients with biliary tract disease, acute pancreatitis, or following gastrointestinal surgery due to constriction of sphincter of Oddi.","Risks of gastrointestinal obstruction (e.g., paralytic ileus) in patients with underlying GI disorders.","Risk of severe constipation; consider prophylactic laxatives.","Monitor for signs of tolerance and physical dependence.","Avoid abrupt discontinuation; taper to prevent withdrawal syndrome.","Use with caution in patients with renal or hepatic impairment; may require dose adjustment.","Risk of falls due to cognitive impairment and motor instability.","May impair mental or physical abilities needed for driving or operating machinery."] |